In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: Are they laboratory artefacts?

Platelets

Volumn 20, Issue 2, 2009, Pages 131-134

  Grignani, Claudio ^a   Noris, Patrizia ^a   Tinelli, Carmine ^b   Barosi, Giovanni ^b   Balduini, Carlo L ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Laboratory artefact; Myeloproliferative disorders; Platelet aggregation; Thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN;

ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOCYTOSIS;

ARTIFACTS; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MYELOPROLIFERATIVE DISORDERS; PLASMA; PLATELET AGGREGATION; PLATELET COUNT; PLATELET FUNCTION TESTS;

EID: 61649084981     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100802691544     Document Type: Article

References (13)

1. Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2004;128:275-290.
2. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils. Semin Hematol 2005;42:239-247.
3. Blann A, Caine G, Bareford D. Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count. Platelets 2004;15:447-449.
4. Robertson B, Urquhart C, Ford I, Townend J, Watson HG, Vickers MA. et al. Platelet and coagulation activation markers in myeloproliferative diseases: Relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007;5:1679-1685.
5. Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991;95:82-86.
6. Avram S, Lupu A, Angelescu S, Olteanu N, Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J Cell Mol Med 2001;5:79-87.
7. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006;32:589-604.
8. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: Autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007;92:694-697.
9. Jennings LK, McCabe White M. Platelet aggregation. In: Alan D, Michelson AD, editors. Platelets, 2nd ed., Burlington: Academic press; 2007. pp 495-507.
10. Balduini CL, Sinigaglia F, Damiani G, Bertolino G, Bisio A, Zocchi E. Effect of a monoclonal antibody against GPs IIb-IIIa on platelet aggregation and ATP secretion. Exp Hematol 1986;13:338-342.
11. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929.
12. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-160.
13. Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med 1978;299:505-509.